Navigation Links
Echo Therapeutics Announces Multiple Patents and Trademark Grants
Date:8/8/2011

PHILADELPHIA, Aug. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the receipt of notices of issuance for two patents covering its Symphony tCGM System and notices of registration for the trademarks PRELUDE and SYMPHONY.

Echo Therapeutics received notice that its patent application entitled, "System and Method for Continuous Non-Invasive Glucose Monitoring" will issue as U.S. Patent No. 7,963,917. As a result of a patent term adjustment that is expected to add nearly 4 years to the term of the patent, it is expected to expire in 2025.  Echo Therapeutics also received notice that its patent application entitled "Transdermal Analyte for Monitoring Systems and Methods for Analyte Detection" was issued as South Africa Patent No. 2009/06959 and will expire in 2028.  Additionally, Echo has received notice that its applications for the trademark PRELUDE have been registered for use in International Class 10 in South Korea and Mexico; and its application for the trademark SYMPHONY has been registered for use in International Class 10 in Israel.

"We have long recognized the unique value that our non-invasive, glucose monitoring technology can provide, and these patents reinforce this belief, further demonstrating the proprietary nature of our technology," stated Patrick Mooney, M.D., Echo's Chairman and CEO.  "We believe that our intellectual property portfolio will provide our products with long-term market protection and will add significantly to our shareholder value."

These patents join eleven U.S. patents and twenty-eight foreign patents already obtained by Echo Therapeutics.  Over 40 patent applications by Echo are pending in the U.S. and foreign countries.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine Olimpio
Director, Corporate Communications
215.717.4100

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
4. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
5. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
7. Michael Showalter Joins Prime Therapeutics As Chief Marketing Officer
8. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
9. Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market
10. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
11. Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... , ... Shark Finds and Kevin Harrington, along with the Product ... with Belly Bands. , Having a dog is great—except when it wets every couch, ... nothing works, get Belly Bands, the easiest way to stop dogs from wetting ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The Muscular Dystrophy Association and Sailormen Inc., ... 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise critical ... diseases that severely limit strength and mobility. , Now through March 20, ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an ... Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the ... successfully completed his first three-year term as chief and began a second three-year term ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
Breaking Medicine News(10 mins):